European opposition to exclusive control over predictive breast cancer testing and the inherent implications for U.S. patent law and public policy: a case study of the Myriad Genetics' BRCA patent controversy
Affiliations
- PMID: 15190928
Item in Clipboard
European opposition to exclusive control over predictive breast cancer testing and the inherent implications for U.S. patent law and public policy: a case study of the Myriad Genetics' BRCA patent controversy
Food Drug Law J.
2004.
No abstract available
Similar articles
-
Patents. U.S. appeals court hears gene patent arguments.Science. 2012 Jul 20;337(6092):277-8. doi: 10.1126/science.337.6092.277. Science. 2012. PMID: 22822118 No abstract available.
-
Ruling on BRCA gene patents could have limited impact.J Natl Cancer Inst. 2010 Jun 2;102(11):754-7. doi: 10.1093/jnci/djq209. Epub 2010 May 24. J Natl Cancer Inst. 2010. PMID: 20498427 No abstract available.
-
History of a gene patent: tracing the development and application of commercial BRCA testing.Health Law J. 2002;10:123-46. Health Law J. 2002. PMID: 14748275 No abstract available.
-
The European opposition against the BRCA gene patents.Fam Cancer. 2006;5(1):95-102. doi: 10.1007/s10689-005-2580-6. Fam Cancer. 2006. PMID: 16528613 Review.
-
Intellectual property and biotechnology: the European debate.Kennedy Inst Ethics J. 2007 Jun;17(2):69-110. doi: 10.1353/ken.2007.0008. Kennedy Inst Ethics J. 2007. PMID: 18018994 Review.
Publication types
MeSH terms
LinkOut - more resources
Medical